Markets

Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat

Oct 1, 2026 · 06:59 AM ET· updated 16h ago

Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooledsemaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without

Why It Matters

Novo's weight loss medicine helped most people reduce harmful liver fat. This suggests the drug might help with health problems beyond just weight.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NVO37.42

-0.49 (-1.31%)

LLY1,150.98

-6.10 (-0.53%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.